JPMorgan Chase & Co. Issues Pessimistic Forecast for Tempus AI (NASDAQ:TEM) Stock Price

Tempus AI (NASDAQ:TEM) had its target price cut by analysts at JPMorgan Chase & Co. from $80.00 to $60.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 10.85% from the stock’s previous close.

Several other analysts have also commented on the company. HC Wainwright cut their price objective on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a report on Friday, November 7th. BTIG Research dropped their target price on Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday. Mizuho began coverage on shares of Tempus AI in a research report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price target for the company. Robert W. Baird assumed coverage on shares of Tempus AI in a report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Eight research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average target price of $80.92.

Tempus AI Stock Performance

TEM stock traded down $3.82 on Wednesday, hitting $54.13. The company had a trading volume of 6,627,362 shares, compared to its average volume of 5,707,368. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. Tempus AI has a 12-month low of $36.22 and a 12-month high of $104.32. The stock has a market cap of $9.63 billion, a price-to-earnings ratio of -45.47 and a beta of 5.22. The stock’s 50-day simple moving average is $61.92 and its 200 day simple moving average is $73.59.

Insider Activity at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 10,949 shares of Tempus AI stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $60.31, for a total transaction of $660,334.19. Following the transaction, the executive vice president owned 126,918 shares of the company’s stock, valued at $7,654,424.58. The trade was a 7.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ryan Fukushima sold 9,592 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $566,407.60. Following the completion of the sale, the chief executive officer directly owned 694,354 shares of the company’s stock, valued at approximately $41,001,603.70. This trade represents a 1.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 596,035 shares of company stock worth $37,505,125 in the last 90 days. Insiders own 26.27% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

Several large investors have recently made changes to their positions in the business. Cranbrook Wealth Management LLC purchased a new stake in shares of Tempus AI during the third quarter worth about $25,000. JPL Wealth Management LLC bought a new position in Tempus AI in the 3rd quarter worth approximately $26,000. Los Angeles Capital Management LLC purchased a new stake in Tempus AI during the 4th quarter valued at approximately $27,000. GAMMA Investing LLC purchased a new stake in Tempus AI during the 3rd quarter valued at approximately $28,000. Finally, Allworth Financial LP raised its position in shares of Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after buying an additional 450 shares during the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Very strong revenue growth — Q4 revenue jumped ~83% YoY, beating consensus and showing broad strength across Diagnostics, MRD and Data businesses; RCV and retention metrics also look healthy. MarketBeat Q4 recap
• Positive Sentiment: FY‑2026 revenue guide is sizable — management outlined roughly $1.59B in 2026 revenue (≈25% growth guidance), which implies continued top‑line momentum and gives a clear growth runway to model. Seeking Alpha: 2026 revenue target
• Positive Sentiment: Margins improving — management reported narrower losses, higher gross profit and an adjusted EBITDA inflection to positive on a YoY basis, supporting the path to eventual sustained profitability. MarketBeat analysis
• Neutral Sentiment: Product/partnership expansion continues — launches like the HRD‑RNA algorithm and a lung‑screening partnership expand addressable market and could support longer‑term revenue, but near‑term financial impact is incremental. Yahoo Finance: product & partnership update
• Neutral Sentiment: Analysts largely remain constructive — several firms kept Buy/Overweight ratings (Morgan Stanley kept a $85 PT; Canaccord and others reiterated positives), showing institutional support despite the pullback. TipRanks: analyst notes
• Negative Sentiment: Profitability details disappointed some investors — headlines and market reaction focused on a wider‑than‑expected loss / operating shortfall in Q4 and ambiguity on the timing of full‑year profitability inflection, which undercut sentiment. Zacks: earnings miss / reaction
• Negative Sentiment: Price‑target cut and valuation concerns — BTIG trimmed its target from $105 to $90 (still constructive), highlighting mixed near‑term expectations; high leverage and elevated short interest add downside risk in volatile trading. Benzinga: BTIG target cut
• Negative Sentiment: Market reaction: despite beat‑and‑raise elements, investors sold on the mixed profit signal and cautious tone — that combination explains today’s pullback. 247WallSt: mixed reaction

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.